Effect of Equivalent Dose of Alfentanil and Sufentanil Combined With Remimazolam in Complex Bronchoscopic Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- time of Recovery
研究概览
简要总结
The equivalent dose of sufentanil and afentanil combined with laryngeal mask was used for complex bronchoscopy to observe the intraoperative effect and the influence on the recovery of patients
详细描述
Afentanil is a powerful, fast-acting narcotic analgesic, which can effectively inhibit intubation reflex. Compared with sufentanil, it has a short half-life and is safer, and can be used as the first choice for short surgical analgesics. In this study, by comparing the use of equivalent dose sufentanil and afentanil combined with laryngeal mask for complex bronchoscopy, the intraoperative analgesic effect and the influence on the recovery of patients were observed, and a better anesthesia scheme was provided for tracheoscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80,
- •ASA I-III level;
- •BMI 18.5~23.9;
排除标准
- •Patients with full stomach and high risk of reflux aspiration;
- •Allergic to benzodiazepines, opioids, rocuronium bromide;
- •Those who have taken sedative, analgesic or antidepressant drugs within 24 hours;
- •Pregnant and lactating women;
- •severe liver and kidney dysfunction;
- •Patients with severe anemia and hypoproteinemia;
- •Previous drug use history;
- •Recently participated in other clinical studies;
- •Patients who cannot cooperate with communication.
研究组 & 干预措施
Alfentanil
The dose of aifentanil group is 10μg/kg
干预措施: Alfentanil (Drug)
Sufentanil group
The dose of sufentanil group is 0.2μg/kg
干预措施: Alfentanil (Drug)
结局指标
主要结局
time of Recovery
时间窗: 1day
the time from the end of surgery to awake of patient
次要结局
- Time records(1 day)
- dose of drugs(1 day)
- rate of respiratory suppression incidence(1 day)
- rate of Incidence of Treatment-Emergent Adverse Events(1day)